Predictmedix AI Inc. (CSE:PMED, OTCQB:PMEDF), a leader in rapid health screening solutions, has announced a strategic partnership with KGK Science, a prominent contract research organization. This collaboration aims to leverage the power of artificial intelligence (AI) to transform health research, product development, and patient screening processes.
The partnership marks the introduction of a new “high-potential” vertical for Predictmedix. By integrating its AI-powered technologies into KGK Science’s clinical trials, the company envisions redefining patient screening accuracy, enhancing data collection, and introducing continuous monitoring methods. This integration has the potential to significantly boost clinical trial efficiency, leading to cost savings and improved return on investment for research organizations.
“Our partnership with KGK Science aligns perfectly with our shared vision of using cutting-edge health assessment technologies to create new possibilities in health research and product development,” stated Rahul Kushwah, COO of Predictmedix AI. “We are deeply committed to this collaboration, which will enable us to innovate and elevate the standards of health assessments.”
Predictmedix AI’s innovative Safe Entry Stations utilize proprietary AI and multispectral cameras to analyze physiological data patterns and predict various health concerns, including 19 vital signs, drug or alcohol impairment, fatigue, and even certain mental illnesses. This partnership will allow KGK Science to leverage these advanced capabilities within their clinical trials, potentially leading to groundbreaking advancements in healthcare.
